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n an era of growing suspicion
toward "big govemme nt," a long.lime Washington insider came to
the University at Buffalo on Oct.
26. 1998, to deliver a hig hly
charged account of one federal agency's
activist role in American life: the fede ral
Food and Drug Administration.
Peter Batt on Hutt , who grew up in
Kenmore, N.Y., serve d as chie f counsel
for the FDA from 1971 to 1975. Now he
specializes in food and drug law in his
practice with the Washington law firm
Covi ngton & Burling, a nd teaches on
that subject at Harvard and Stanford law
schools. At his lecture in the Ce nter for
the Arts, jointly sponsored by UB Law
School and the university's dental
school, Hutt told how an agency that
began in the 1830s as a rrtinor offshoot
of the U.S. Pate nt Office has since grown
to become "the single most impotiant
component of government that we have
in our society . The FDA regulates 25
percent of the American economy," he
said. "That is a staggering figure when
you thi nk of it."
Its charge is to regulate foods,
drugs and medical devices, but fa r from
its activist role of today, the early FDA
served as a "policeman" forcing food
manufacturers and distributors to clean
up their act and prevent adulteration of
the nation's food supply. It was afler 120
people died in one day in.September
l 937. when tht> introduc tion of a new
drug proved poisonous. that Congress
passed laws requiring that the government be notified befo re new drugs were
introduced to the marketplace.
What followed was a steady expansion of the fDA's powers, Hutt said, as
thl' agPney broaclen<'d its reach to cont!'Ol l)(•stirid<· r<·sidues o~ food. fo~Jd
additiws and colorings. tn troducttons of
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new drugs, and finally
medical devices.
Congress decided that
none of these drugs and
devices should go on
the mar ket witl1out
FDA approval, hence
the agency's powerful
new role as gate keeper
and ru le-make r to thi s
lucrative industry.
'These we re
statutes," Hutt said,
"that usually were crealeel in a crisis altnosphere, because of one
tainted product or one
consume r who was made sick."
For decades, he said, the agency
was the focus of de bate over the "drug
lag" - many drugs widely available in
Europe were not sold in the United
States, a fact many blamed on the great
numbe r of FDA regulations gove rni ng
the testing and approval of pharmaceuticals. "It is unclear," he said, "whe the r
the drug lag's net effect is positive or
negative. One opinion is that the
American people must be protected at
all costs, and if the cost of that is delay in
the introduction of new medical technology, so be it. You can always find a drug
or device that has hu rt someone. Those
are real pe ople and you can fi nd the m.
What you can't find , and what no newspaper ever emphasizes, are those people
who are harmed by the delay in medical
technology."
The issue came to the forefront in ·
the latE' 1980s and e arly 1990s, he aid.
largely bE'cause of grass-roots activism
by the gay communi ty in response to the
Al DS crisis. "P<'opll' began to realize the
drug lag is not an abstract problem," he
said. Gay attivists marched on the

agency, some eve n chaining themselves
to the fron t door of the FDA build ing in
Wash ington, demanding accele rated
approval for promising anti-AIDS dm gs.
The agency responded, and in subsequent years advocates for other ill
Americans, suffering from such maladies as cance r and heati disease, added
their voices to the chorus pushing for
faster dmg approvals.
Meanwhile, Hutt said ,
the Republicans'
Congressional "budget
revolu tion" was flatteni ng
FDA's spending allocation. At the same time.
the White House has proposed such new progra ms as a food safety
in itiative, and next-generation issues such as gene
the rapy a nd cloning are
demand ing attention.
The age ncy, squeezed for
resources, broke with
tradition and began to
charge user fee s for newdrug applications. 1l1e
FDA hi red 500 ne w drug reviewers a nd
cu t its review time for applications in
hall- a huge savings for drug companies, he said. Because it is so expensive
to introduce a new drug , faster approval
increases the firms' return on investmen t rapidly.
Hutt told U1e audience of about 65
people that the latest revision in ~he .
age ncy's work, the FDA Modern tzalton
Act of 1997, among othe r things a llowe d
the sale of die tary suppleme nts withou t
FDA approval - a blow to the agen.cy.
which had waged a 75-year war agamst
such product s as being useless.
Other reforms have been enacte d.
and more have been urged by various .
inte rests. but still, Hutt said, "we hav~ 111
a true sense no cohe rent pharm~ceu~cal
policy in this count ry. The FDA.ts trymg
hard to do its job the same way tt has
done for the past century. The single
g reatest need is leadership at the top of
the FDA. We need a leade r who does
not see regulation as confro ntati_on_. but
rathe r as coopE'ration and negottatton.
"Afte r all. it is thE' healtl1 of the ,.
Ametican people we are tall<ing about. •

